# Odyssey Therapeutics, Inc. (ODTX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $16.86 (+4.07%)

> Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with autoimmune and inflammatory diseases. The company advances a pipeline of small molecule and protein therapeutics that target upstream signaling nodes in the innate immune system to prevent pathological inflammation. Key programs include OD-001, an oral small molecule RIPK2 scaffolding inhibitor for ulcerative colitis and Crohn’s disease; OD-002, an SLC15A4 inhibitor for cutaneous lupus erythematosus, nephropathies, and B cell-mediated diseases; and OD-003, a TNFR2 agonist protein therapeutic for atopic dermatitis, systemic lupus erythematosus, and alopecia areata. Additional candidates address TSLP/IL-33 for asthma and COPD, IRAK4 scaffolding for atopic dermatitis and hidradenitis suppurativa, and IRF5 in collaboration with partners. Founded in 2021 and headquartered in the United States, Odyssey Therapeutics leverages expertise in immunology to create precise treatments that modulate inflammatory dysregulation, aiming to address significant unmet needs in immunology through selective targeting of disease-relevant pathways.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/ODTX)